Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: The state of the art and potential applications

Journal of Nuclear Medicine

Volumn 51, Issue 10, 2010, Pages 1549-1558

  Kwee, Thomas C ^a   Takahara, Taro ^a   Ochiai, Reiji ^b   Koh, Dow Mu ^c   Ohno, Yoshiharu ^d   Nakanishi, Katsuyuki ^e   Niwa, Tetsu ^a,f   Chenevert, Thomas L ^g   Luijten, Peter R ^a   Alavi, Abass ^h  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Koga Hospital 21   (Japan)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

18F fluoro 2 deoxyglucose; Diffusion weighted magnetic resonance imaging; DWI; FDG PET; Position emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BLADDER CARCINOMA; BRAIN; BRAIN ISCHEMIA; CANCER DIAGNOSIS; CLINICAL EVALUATION; COLORECTAL CANCER; COMPARATIVE STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFUSION; DIFFUSION WEIGHTED IMAGING; ENDOMETRIUM CARCINOMA; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG DISEASE; LYMPH NODE METASTASIS; MEDLINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; WHOLE BODY MRI;

DIFFUSION MAGNETIC RESONANCE IMAGING; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; WHOLE BODY IMAGING;

EID: 79851491108     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.073908     Document Type: Review

References (58)

1. Alavi A, Reivich M. Guest editorial: the conception of FDG-PET imaging. Semin Nucl Med. 2002;32:2-5. (Pubitemid 34112938)
2. 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
3. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med. 2009;39:36-51.
4. 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008;49(10):17N-21N, 37N.
5. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004;22:275-282.
6. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR. 2007;188:1622-1635. (Pubitemid 46866868)
7. Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008;18:1937-1952.
8. Bischof Delaloye A, Carrió I, Cuocolo A, et al. White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging. Eur J Nucl Med Mol Imaging. 2007;34:1147-1151. (Pubitemid 47290677)
9. Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51:333-336.
10. Sotak CH. Nuclear magnetic resonance (NMR) measurement of the apparent diffusion coefficient (ADC) of tissue water and its relationship to cell volume changes in pathological states. Neurochem Int. 2004;45:569-582.
11. Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology. 2000;217:331-345.
12. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102-125.
13. Lee JH, Springer CS Jr. Effects of equilibrium exchange on diffusion-weighted NMR signals: the diffusigraphic "shutter-speed." Magn Reson Med. 2003;49:450-458.
14. Zhang JL, Sigmund EE, Chandarana H, et al. Variability of renal apparent diffusion coefficients: limitations of the monoexponential model for diffusion quantification. Radiology. 2010;254:783-792.
15. Maier SE, Bogner P, Bajzik G, et al. Normal brain and brain tumor: multicomponent apparent diffusion coefficient line scan imaging. Radiology. 2001;219:842-849. (Pubitemid 32476283)
16. Bennett KM, Schmainda KM, Bennett RT, Rowe DB, Lu H, Hyde JS. Characterization of continuously distributed cortical water diffusion rates with a stretched-exponential model. Magn Reson Med. 2003;50:727-734. (Pubitemid 37187837)
17. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9:53-60. (Pubitemid 29068231)
18. Uto T, Takehara Y, Nakamura Y, et al. Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology. 2009;252:247-254.
19. Hamstra DA, Galbán CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387-3394.
20. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res. 2009;15:986-994.
21. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology. 2008;248:894-900.
22. Liu Y, Bai R, Sun H, Liu H, Zhao X, Li Y. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol. 2009;64:1067-1074.
23. Hardie AD, Naik M, Hecht EM, et al. Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol. 2010;20:1431-1441.
24. Koh DM, Brown G, Riddell AM, et al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol. 2008;18:903-910.
25. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR. 2007;189:323-328. (Pubitemid 47195916)
26. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection - a multireader study. Radiology. 2009;250:145-151.
27. Ichikawa T, Erturk SM, Motosugi U, et al. High-B-value diffusion-weighted MRI in colorectal cancer. AJR. 2006;187:181-184. (Pubitemid 46100166)
28. Ichikawa T, Erturk SM, Motosugi U, et al. High-b value diffusion-weighted MRI for detecting pancreatic adenocarcinoma: preliminary results. AJR. 2007;188:409-414. (Pubitemid 46167742)
29. Inada Y, Matsuki M, Nakai G, et al. Body diffusion-weighted MR imaging of uterine endometrial cancer: is it helpful in the detection of cancer in nonenhanced MR imaging? Eur J Radiol. 2009;70:122-127.
30. Nakanishi K, Kobayashi M, Nakaguchi K, et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci. 2007;6:147-155.
31. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008;248:643-654.
32. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, wholebody FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging. 2009;30:298-308.
33. Kwee TC, Quarles van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol. 2009;44:683-690.
34. Humphries PD, Sebire NJ, Siegel MJ, Olsen ØE. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology. 2007;245:848-854.
35. Feuerlein S, Pauls S, Juchems MS, et al. Pitfalls in abdominal diffusion-weighted imaging: how predictive is restricted water diffusion for malignancy. AJR. 2009;193:1070-1076.
36. Sumi M, Sakihama N, Sumi T, et al. Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR. 2003;24:1627-1634. (Pubitemid 37151732)
37. Sumi M, Van Cauteren M, Nakamura T. MR microimaging of benign and malignant nodes in the neck. AJR. 2006;186:749-757. (Pubitemid 46100259)
38. King AD, Ahuja AT, Yeung DK, et al. Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology. 2007;245:806-813. (Pubitemid 350127351)
39. Kim JK, Kim KA, Park BW, Kim N, Cho KS. Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging. 2008;28:714-719.
40. Park SO, Kim JK, Kim KA, et al. Relative apparent diffusion coefficient: determination of reference site and validation of benefit for detecting metastatic lymph nodes in uterine cervical cancer. J Magn Reson Imaging. 2009;29:383-390.
41. Vandecaveye V, De Keyzer F, Vander Poorten V, et al. Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology. 2009;251:134-146.
42. Kwee TC, Takahara T, Luijten PR, Nievelstein RA. ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol. April 15, 2009 [Epub ahead of print].
43. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55:761-769.
44. Sakurada A, Takahara T, Kwee TC, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol. 2009;19:1461-1469.
45. Nasu K, Kuroki Y, Sekiguchi R, Kazama T, Nakajima H. Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med. 2006;24:438-444.
46. Kwee TC, Takahara T, Niwa T, et al. Influence of cardiac motion on diffusion-weighted magnetic resonance imaging of the liver. MAGMA. 2009;22:319-325.
47. Ohno Y, Koyama H, Nogami M, et al. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. J Magn Reson Imaging. 2007;26:1071-1080. (Pubitemid 47548169)
48. Tsushima Y, Takano A, Taketomi-Takahashi A, Endo K. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images. Acad Radiol. 2007;14:643-650. (Pubitemid 46898198)
49. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-314. (Pubitemid 126789027)
50. Mori T, Nomori H, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol. 2008;3:358-364. (Pubitemid 351489475)
51. Ohba Y, Nomori H, Mori T, et al. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg. 2009;138:439-445.
52. Kanauchi N, Oizumi H, Honma T, et al. Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg. 2009;35:706-710.
53. Nomori H, Mori T, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg. 2008;135:816-822. (Pubitemid 351417933)
54. Ono K, Ochiai R, Yoshida T, et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDGPET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging. 2009;29:336-340.
55. Choi EK, Kim JK, Choi HJ, et al. Node-by-node correlation between MR and PET/CT in patients with uterine cervical cancer: diffusion-weighted imaging versus size-based criteria on T2WI. Eur Radiol. 2009;19:2024-2032.
56. Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging. 2009;36:200-208.
57. Stecco A, Romano G, Negru M, et al. Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study. Radiol Med (Torino). 2009;114:11-17.
58. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39-45. (Pubitemid 34101186)